





NORTHERN ILLINOIS UNIVERSITY 
 
Vision’ary: Drug Delivery for Ocular Diseases 
 
A Thesis Submitted to the 
 
University Honors Program 
 
In Partial Fulfillment of the 
 
Requirements of the Baccalaureate Degree 
 



















Abstract Retinal ocular diseases such as age-related macular degeneration (AMD), clinically significant diabetic macular edema 
(DME), diabetic retinopathy (DR) and retinal vein occlusions are currently difficult to treat effectively with topical medications 
and eye drops. Intravitreal injections of pharmacological products are currently the most effective method of treatment. Frequent 
injections have been found to have adverse effects including infection, endophthalmitis and retinal detachment.  Inconsistent 
patient compliance decreases the effectiveness of the pharmaceuticals and the fiscal impact also poses a problem with recurring 
intravitreal injections. Liposomes are nano-sized bi-layered vesicles that will encapsulate various hydrophilic or hydrophobic 
substances necessary for treatment of ocular diseases. Liposomes can be formulated to slowly release the drug thereby preventing 
frequent painful injections. Liposomes of various lipid to cholesterol concentrations were formulated using the ethanol-injection 
method and then extruded with a 100 nm pore sized polycarbonate filter. The liposomes were then characterized via confocal 
microscopy, dynamic light scattering, and transmission electron microscopy to analyze size, homogeneity, stability, and 




HERE are many barriers encountered when 
attempting ocular drug delivery to the retina. Drugs 
cannot be easily delivered to the retina by topical methods 
like eye drops because of structural barriers including the 
cornea and the lens. Figure 1 shows the anatomy of the eye 
illustrating the retina, the light sensitive layer of the eye. A 
localized portion of the retina is the macula, encasing the 
rods and cones, allowing sight in both the dark and in the 
light. Systemically administered drugs seldom enter the 
retina because of the blood/aqueous barrier and the 
inner/outer blood retinal barriers, consisting of retinal 
capillary endothelial cells and retinal pigment epithelium 
cells (RPE), therefore leaving intravitreal injection the 






Fig. 1 Anatomy of the eye 
3 
 
Current drug delivery options include eye drops, 
intravitreal injections and liposomes. Eye drops that are 
administered for acute ocular diseases are often 
inconsistent in the effectiveness and can cause dry eye 
and allergic conjunctivitis. It has been reported that 80% 
of the drops administered exit the eye via the lacrimal 
duct after two minutes and only 5% of the free drug 
enters after tearing.
1,2  
Musin, produced by the tears, forms a hydrophilic 
barrier around the outer layer of the eye preventing 
foreign particles from adhering and entering the topical 
layers.
4 
The exterior of the eye is split into the epithelium, 
stroma, and endothelium.
5 
Figure 2 highlights the 
individual layers of the cornea.
6
 The exterior stroma and 
epithelium of the cornea and conjunctiva form a blockade 








, Dr. Elizabeth Gaillard
1,2
 
Northern Illinois University, Dept. of Chemistry and Biochemistry
1








preventing diffusion of most drugs.
4
 Tight cell junctions, 
lipophilicity and pKa are the determining factors in what 
can and cannot enter the cornea.
1,7 
 
Fig. 2 Layers of the cornea 
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Intravitreal injection of pharmaceuticals have recently 
been used for the treatment of several ocular diseases 
including age-related macular degeneration (AMD), 
clinically significant diabetic macular edema (DME), 
diabetic retinopathy (DR) and retinal vein occlusions. These 
ocular diseases dramatically influence the quality of life of 
more than 8 million people worldwide.
4 
The major ocular 
disorders of Americans forty years or older create a fiscal 
impact of $35.4 billion.
8 
Injections, in the form of solutions, particulates, or 
suspensions, targeted at the retina must pierce the pars plana 
(Fig. 3). The benefits of these intravitreal injections include 
transcending issues from eye drops, allowing direct contact 
with the posterior eye, and reducing systemic effects caused 
by oral medications.
9
 Many risk factors are associated with 
intravitreal injections including: infection of the ocular 
surface, infection caused by contaminated surgical 
equipment or pathogens, pain, swelling, increased ocular 
pressure and retinal detachment.
2,10 
The viscosity of the 
drug being administered may convolute the natural vitreous 
humor, containing collagen and hyaluronic acid inside the 
eye cavity, causing localized complications and decreased 
vision.
4,10,11
 If the solution injected is more dense than water 
it may fall to the bottom of the eye due to gravity, ceasing to 
be therapeutic.
12 
The negative overall charge of the vitreous, 
due to the hyaluronic acid, induces positive particles to 
aggregate within the eye making the charge extremely 
important in respect to the injection of medications.
4
   The 
mode of intravitreal injection into the eye is via a 27-30 
gauge syringe.
13
 It should be noted that the volume of the 
aqueous humor in the eye is approximately 1 milliliter so 






Fig. 3 Injection through the pars plana of eye 
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Free drugs administered intraocularly tend to have short 
half-lives and frequent injections are necessary for 
satisfactory treatment.
9, 15 
This half-life is dependent upon 
the route that the drug takes once inside the aqueous humor, 
the jelly-like solution inside the eye cavity. The drug may 
be diffused into the aqueous humor and eliminated via its 
rejuvenation or the blood.
 
It may also cross the blood/brain 




AMD can be subdivided into wet and dry. Dry AMD is 
categorized by the formation of a defined, vascular, circular 
area forming on the retina with a pale color due to 
diminished pigment. Patients have a loss of vision in a 
localized area. The wet form is indicative of a fluid layer 
forming in the Bruch’s membrane and causing the RPE cells 
to detach. This interference with the photo receptors induces 
blurry vision called metamorphopsia and may lead to 
permanent blindness.
16 
The liposomal preparation for our studies focuses on the 
disease process of wet AMD. For decades the treatment of 
ocular diseases via intravitreal injection has been used to 
administer steroids for the treatment of AMD.
13 
This 
particular ocular disease affects central vision and is caused 
by a deterioration of the photoreceptors in the macula. The 
first signs of AMD are hyper or hypo pigmentation of the 
RPE cells.
8
 A build-up of drusen underneath the RPE cells 
creates a layer of fragmented lipids, cellular components, 
vitamin A by-products and proteins. The pathogenesis of 
the disease is not currenty understood, but many theories 
have been postulated including damage by oxidation, non-
functioning RPE or Bruch’s membrane, increased apoptosis, 
immune response, or lipofuscin aggregation.
8 
There is now 
contention that the two forms of AMD, wet and dry, are two 
different disease processes.  
Repetitive injections lead to decreased patient 
compliance and substantial increase in cost. Placement of 
these drugs in capsulated particles increases the duration of 
effectiveness of these drugs by 3-6 months thus decreasing 
the frequency of injections.
9 
There are currently no FDA approved long term delivery 




A more direct application of ocular medications is needed 
in order for the performance of the drugs to be significantly 
effective and a long-term release process to decrease risk of 
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patient compliance, decrease cost, and risk of infection. 
 
The solution to these aforementioned problems may lie in 
the treatment of ocular diseases with liposomes. Liposomes 
are spherical vesicles made up of a lipid bi-layered 
membrane that plays an important role in the encapsulation 
of drugs in particular but also can enclose proteins, 
enzymes, antibiotics, hormones and viruses.
2, 18
 A 
hydrophobic layer lies within the nonpolar tails of the 
bilayer where hydrophobic drugs can be positioned and a 
hydrophilic core where hydrophilic drugs can be contained, 
allowing the liposome to have an ampiphillic quality.
11, 18 
There exist various lipid compositions both in nature and 
bioengineered liposomes. Phosphotidylcholine (PC), Fig. 4, 
has been found to be a viable lipid used in the formation of 
liposomes. This lipid is the makeup of many biological 
membranes and is important in cell membrane signaling.
19
 It 
is the most abundant phospholipid in animals, plants and 
can be found in egg yolk.
20
 Because of its cylindrical shape, 
PC spontaneously forms a bilayer so it is ideally suited for 
the bulk of the plasma membrane or, in this case, the 
liposome bilayer.
11
 This molecule contains a choline polar 
head group with hydrocarbon non-polar tails and is 
categorized as a glycerophospholipid.
21 
The unsaturated 
acyl chains are linked and confer fluidity on the membrane. 
The amphipathic bilayer not only surrounds the hydrophilic 
core where hydrophilic drugs can be contained, but 






Fig. 4 Structure of Phosphatidylcholine 
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To prevent the liposome from being too fluid, prevent 
leakage and reduce permeability, cholesterol (CH) can be 
added to the liposome formulation, filling in the free space 
between the lipids.
22, 23
 The molecular structure of 
cholesterol is depicted in Fig. 5. The body of cholesterol 
consists of a series of fused rings that make the molecule 
quite rigid. At one end of this planar ring system is a 
hydroxyl group and at the other end is a hydrocarbon tail, so 
cholesterol, like other membrane lipids, has both 
hydrophilic and hydrophobic poles that determine its 
positioning within the lipid bilayer.
21
 When the hydroxyl 
group is next to the phospholipid ester carbonyl, the rigid 
body of cholesterol is situated alongside the fatty-acid tails 
of neighboring phospholipids and can help to order these 
tails (Fig. 6). 
 
 









The main parameters of our liposomes are slow release 
and stability. We want to utilize them as a slow release 
vesicle. Encapsulation stability and entrapment is extremely 
important in our formulations. The quality must be 
maintained so no leaking occurs of the drug prematurely. 
Encapsulation prevents the drug from interacting with 
surrounding molecules and being metabolized by enzymes 
and thereby reducing the drug’s effectiveness.18  
The actual manufacturing method and preparation also 
needs to be taken into account when thinking wide scale 
production. Proper materials need to be used to prevent any 
cytotoxicity and cell death to the fragile tissues of the eye.
15
 
Systemic affects also need to be considered when 
administering any form of the drug. 
23
  
Liposomes are also currently being researched and 
developed for the treatment of cancer and respiratory 
diseases by adding polyethylene glycol (PEG) to the 
liposome formulation to improve encapsulation efficiency 
and to attach PEG conjugates for specific binding and 
uptake by the target cell.
15, 24
 PEG liposomes are also 
proven to prevent fusion and aggregation.
25
 Studies are also 
in effect to deliver encapsulated drugs via eye drops 
although no substantial evidence is confirmed that 
liposomes can penetrate the outer surface.
7, 26 
Size plays an important role in the preparation of 
liposomes. Liposomes must be in the nano-size range to be 
a potential drug carrier targeting the retina.
18
 The larger the 
particle, the more light scattering will occur, interfering with 
vision.
11 
Nanoparticles up to 500 nanometers in diameter 
that bypass the possible obstruction of steric hindrance in 
the vitreous humor, having no PEG attachments have been 
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found to be distributed quickly through the internal eye. 
Particles larger than 500 nanometers can interact with the 
vitreous and remain in the gelatin like material, never 
reaching the retina.
9 
An advantage of liposomes without 
PEG attachments eliminates the need for covalent 
interactions which may decrease the activity of the 
PEGylated molecule.
11 
The surface area of each particle is very large compared 
to the volume and the size making them more soluble. 
Therefore the drug can dissolve more readily and become 
bioavailable in the body. They also need to have the ability 
to hold a homogeneous liposome size that are stable and can 
hold their encapsulated payload.
4
 These are the primary key 
elements to be studied for an effective liposome carrier.  
Due to the size of small uni-lamellar vesicle (SUV, 20-50 
nanometers) or large uni-lamellar vesicle (LUV, 100 
nanometers), direct uptake by the eye has been shown 
ineffective. Studies state that SUV have a shorter half-life 
than LUV.
20 
In order to determine optimal release stability we 
formulated and produced liposomes with various lipid to 
cholesterol molar ratios and formed liposomes via ethanol-
injection method and extrusion to observe the resulting 
stability, size, aggregation, and encapsulation efficiency via 
transmission electron microscopy (TEM), confocal 
microscopy (CM), and dynamic light scatterer (DLS). 
II. MATERIALS AND METHODS 
A. Materials 
The phosphatidylcholine, cholesterol, 100% ethanol, 
florescein and vitamin E were purchased from Sigma. The 
glass syringes used for the ethanol injection were Hamilton 
500 microliters or 100 microliters. The Lipex extruder was 
purchased from Northern Lipids. The polycarbonate filters 
are Whatman. The injection machine is Hamilton. The DLS 
is Brookhaven and the confocal is Nikon. 
B. Preparation of Liposomes 
Vesicles were prepared using dry PC and CH with 10:1, 
8:6, 8:4, and 8:2 PC/CH molar concentration mixtures and 
were hydrated with 3mL of 100% ethanol. Liposomes were 
stored at 4 ºC. The samples were alliquotted to 500 µL. 
Vitamin E was added (1% by volume) to each 500 µL 
sample to prevent oxidation and aggregation of the sample. 
The ethanol-injection method was then used at .5, 2, 4, 6, 8, 
and 10 µL per hour. A 50 or 100 mL glass syringe was used 
and the 500 µL sample was then drawn up with the syringe. 
The needle was loaded into a pump that regulated the 
solutions ejection rate. The bezzle of the needle was placed 
directly underneath the surface of a 10 mM florescein 
solution in a round bottom flask. A spinner bar magnet was 
put in the round bottom flask and the round bottom flask 
was placed on a magnetic plate at a low stir rate. The 
injected samples were dried with an argon gas to remove 
any additional ethanol not encapsulated within the 
liposomes. The round bottom flask remained on the 
magnetic stir plate. The argon gas was an attempt to remove 
any cytotoxic solvent that would be damaging to the eye. 
The liposomes were then extruded using an extruder with 
nitrogen gas 10 times through a .4 µm polycarbonate filter, 
10 times with a .2 µm filter and 10 times with a .1 µm filter 
using aseptic technique.  
C. Characterization of liposomes 
Each sample was then diluted to 10 mM in order to 
characterize using fluorescence microscopy (Fig. 7). The 
liposomes were then viewed using UV (Fig. 8).  The TEM 
(Fig. 9) was used to view the liposomes and note any 
aggregation or large size differential. Images of the 
liposomes (Fig. 10-13) are from the 40 mg/mL sample in 
the 10:1, 8:2, 8:4, and 8:6 ratios. Each sample was also 
characterized using the DLS (Fig. 14) which determined the 
overall size of the liposomes as well as the homogeneity.  
 
1) Evaluation with fluorescence microscopy 
 
Fig. 7 Fluorescence Microscopy 
 
a.  Fluorescence images 
 




2) Evaluation with transmission electron microscopy 
(TEM) 
 
Fig. 9 TEM Instrument 
 
a. TEM images 
 
 
Fig. 10 40 mg/mL 10:1 
 
 
Fig. 11 40 mg/mL 8:6 
 
 
Fig. 12 40 mg/mL 8:4 
 
 
Fig. 13 40 mg/mL 8:2 
 
3) Evaluation with dynamic light scatterer 
 
Fig. 14 Dynamic Light Scatterer Instrument 
III. RESULTS 
Based on the results of the characterization, there is a 
large deviation in the size homogeneity of the 8:6 and the 
10:1 ratios overall.  
 The 8:2 lipid to cholesterol ratio seems to be the most 
stable with the smallest standard deviation in the 40mg/mL 
sample (Fig. 15). In the 50mg/mL sample the 8:2 and the 
8:4 ratios are the most stable (Fig. 16). The 60 mg/mL 8:4 
and 8:2 ratios are currently still being characterized, but 
from the data obtained the trend observed in the previous 
concentrations is consistent (Fig. 17). Overall, the 8:2 ratio 
of the 50 mg/mL sample has the smallest size with the least 
standard deviation (Fig. 18). The injection rate analysis 
indicated that the 10 mL/hr had the smallest size liposome 
whereas the 4 mL/hr had the most consistent sizing 










Fig. 16 50 mg/mL Ratio to size comparison 
 
 
Fig. 17 60 mg/mL Ratio to size comparison 
 
 
Fig. 18 Liposome to size comparison of all ratios 
IV. DISCUSSION 
The ongoing project is geared towards a number of different 
target studies with a goal to ensure the stability of the 
liposomes is sufficient for drug delivery to humans. The 
current research is being conducted in order to synthesize 
and mass produce a stable liposome that is able to release 
the encapsulated drug at a particular duration of time based 
on the drugs specifications.  
Fluorescence lifetimes would be beneficial to observe the 
encapsulation efficiency of these structures. Additional 
samples need to be synthesized between the 40-50 mg/mL 
range to fine tune the best possible ratio as well as 
observing the effects of integrating various combinations of 
lipids into the liposome. Other characterization methods 
may include dissolution, to monitor the rate of release, or 
zeta potential, to monitor the electrical charge on the 
liposomes and thus its plausibility to form aggregates. 
Based on the successful results of a particular method for 
synthesis of the liposome used during present research, the 
efficiency and effectiveness to mass produce liposomes will 
be analyzed. The capability for a particular method of 
synthesis of the liposome will be analyzed for the ease to be 
mass produced efficiently and cost productively.  
Further studies are necessary in order to improve upon 
current practices in ocular healthcare. The formation of 
liposomes as a drug delivery method for ocular diseases is 
the future of ocular health and will decrease many of the 
current complications with current drug delivery methods. 
Due to the increasing age and size of the population, 
improved health and ocular care of age related diseases is 
crucial. Due to this increasing elderly population and the 
number of American’s being affected by these ocular 
diseases, a more effective mode of drug delivery needs to be 
implemented to lower the cost, decrease adverse effects, 
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